Corvus Pharmaceuticals Inc
(Get Free Alerts for CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC
(Get Free Alerts for AZN) for patients with unresectable, stage 3 non-small cell lung cancer.
The average session volume over a 100-day period is about 300,000. Friday's session volume was approaching 120 million at publication time.
AZN News: AstraZeneca announced that "the COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival and objective response rate compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer who had not progressed after concurrent chemoradiation therapy."
The results may be positively impacting Corvus Pharmaceuticals, which has a CD73 asset in its pipeline.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.
https://www.benzinga.com/news/21/09/22990813/whats-going-on-with-corvus-pharmaceuticals-stock-today
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.